Key Players in Thailand Amyloidosis Market | Competitive Landscape 2026

Thailand Amyloidosis Market Overview

According to 6Wresearch, the Thailand amyloidosis market is witnessing steady growth due to increasing awareness of rare diseases, expanding diagnostic capabilities, and the rising adoption of novel therapeutics. The growth is further driven by the high prevalence of hereditary and systemic amyloidosis, growing adoption of genetic testing, and government initiatives to improve healthcare infrastructure. Personalized medicine is growing, particularly in the treatment of transthyretin (ATTR) amyloidosis and light-chain (AL) amyloidosis.

Competitive Landscape

The competitive landscape in the Thailand amyloidosis market is a mix of global pharmaceutical giants and specialized biotechnology firms. These companies provide a wide range of therapeutic options including small molecule drugs, biologics, and novel RNA-targeted therapies.

Leading Players Operating in the Thailand Amyloidosis Market:

1. Pfizer Inc.

A global pioneer in the amyloidosis segment, Pfizer provides Vyndaqel (tafamidis), the standard-of-care stabilizer that handles complex cardiomyopathy and large-scale TTR stabilization.

2. Alnylam Pharmaceuticals, Inc.

A major force in the RNAi space, Alnylam focuses on transforming scientific possibility into reality through innovative gene-silencing therapies like Onpattro and Amvuttra.

3. AstraZeneca PLC

A historic innovator in biopharmaceuticals, AstraZeneca expanded its rare disease footprint through the acquisition of Alexion, focusing on localized clinical solutions for amyloid-related disorders.

4. BridgeBio Pharma, Inc.

A fast-growing leader in the genetic disease segment that provides an end-to-end small-molecule suite, integrating protein stabilization with advanced performance in cardiac clinical trials.

5. Ionis Pharmaceuticals, Inc.

Caters to the rare disease community with an antisense-centric platform that emphasizes precision in RNA-targeted processing and ease of use for administrative healthcare teams.

6. Takeda Pharmaceutical Company Limited

Combines hardware-level diagnostic excellence with pharmaceutical automation, offering plasma-derived therapies and specialized support for systemic amyloidosis in the Asian market.

7. Johnson & Johnson

A mobile-first innovator in the oncology and rare disease space, providing high-precision antibody treatments (like Darzalex) for AL amyloidosis processing across diverse industries.

8. Intellia Therapeutics, Inc.

Leverages decades of CRISPR/Cas9 global experience to provide technology-enabled gene-editing services tailored for the permanent treatment of hereditary amyloidosis.

9. Attralus, Inc.

Provides high-volume pan-amyloid removal solutions and workforce management for diagnostic imaging, supporting some of the newest clinical trials in the country.

10. Prothena Corporation plc

Specializes in protein dysregulation and compliance audits, delivering reliable quaternary care for complex misfolded protein IT operations and legal frameworks.

11. GlaxoSmithKline (GSK)

Provides high-durability pharmaceutical processing and system management solutions, supporting research into SAP (Serum Amyloid P) inhibitors and industrial-scale vaccination frameworks.

12. Alexion Pharmaceuticals

A subsidiary that leverages biometric data to provide high-precision orphan drug access and system processing for diverse industries in the rare disease ecosystem.

13. Neurimmune AG

A regional powerhouse that leverages reverse translational medicine to provide high-quality human-derived antibodies for the treatment of systemic amyloidosis.

14. Sanofi S.A.

Focuses on chronic disease management and diagnostic precision, offering specialized Genzyme-led solutions integrated with comprehensive rare disease support in Southeast Asia.